Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2017 278 648 M
EBIT 2017 -
Net income 2017 67 303 M
Finance 2017 127 740 M
Yield 2017 1,65%
Sales 2018 291 261 M
EBIT 2018 -
Net income 2018 71 850 M
Finance 2018 157 104 M
Yield 2018 1,76%
P/E ratio 2017 21,65
P/E ratio 2018 20,57
EV / Sales2017 5,29x
EV / Sales2018 4,96x
Capitalization 1 603 021 M
More Financials
Company
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of pharmaceutical and diagnostic reagents focusing on prescription pharmaceuticals.Its products include respiratory, digestive, urinary, chemotherapy, hormone, vitamins, and metabolic drugs.The company was founded by Ichibei... 
More about the company
Surperformance© ratings of ONO PHARMACEUTICAL CO., LT
Trading Rating : Investor Rating :
More Ratings
Latest news on ONO PHARMACEUTICAL CO., LT
09/21 ONO PHARMACEUTICAL : European Medicines Agency Validates Bristol-Myers Squibb's ..
08/25 ONO PHARMACEUTICAL : Patent Issued for Prophylactic Agent And/Or Therapeutic Age..
08/09 ONO PHARMACEUTICAL : Influence of Cliical Results from CheckMate-026, a Phase II..
08/08 ONO PHARMACEUTICAL : Bristol-Myers Squibb Announces Top-Line Results from CheckM..
07/27 ONO PHARMACEUTICAL : Submits Supplemental Application of OPDIVO® (Nivolumab) for..
07/14 ONO PHARMACEUTICAL : Notice Concerning Determination of Details of Issuance of S..
07/11 CELYAD : and ONO strike deal for NKR-2 in Japan, Korea and Taiwan
07/11 CELYAD : SA Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunot..
07/11 ONO PHARMACEUTICAL : enters into license agreement with Celyad for its allogenei..
07/06 ONO PHARMACEUTICAL : European Commission approves ONGENTYS® (opicapone) a novel ..
More news
Sector news : Generic Pharmaceuticals
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Generic Pharmaceuticals
Advertisement
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 3 915  JPY
Spread / Average Target 44%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Kazuhito Kawabata Director, Managing Executive Officer & GM-Research
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Kei Sano Director & GM-Corporate Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-37.03%15 857
SUN PHARMACEUTICAL IND..-5.02%28 165
OTSUKA HOLDINGS CO LTD5.19%25 163
BIOMARIN PHARMACEUTICA..-7.03%16 634
ASPEN PHARMACARE HOLDI..5.62%10 757
TAISHO PHARMACEUTICAL ..21.23%9 166
More Results